Cargando…
Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer
Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essentia...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610388/ https://www.ncbi.nlm.nih.gov/pubmed/37895937 http://dx.doi.org/10.3390/ph16101466 |
_version_ | 1785128242921865216 |
---|---|
author | da Silva, Fernanda Cardoso Brandão, Douglas Cardoso Ferreira, Everton Allan Siqueira, Raoni Pais Ferreira, Helen Soares Valença Da Silva Filho, Ademar Alves Araújo, Thaise Gonçalves |
author_facet | da Silva, Fernanda Cardoso Brandão, Douglas Cardoso Ferreira, Everton Allan Siqueira, Raoni Pais Ferreira, Helen Soares Valença Da Silva Filho, Ademar Alves Araújo, Thaise Gonçalves |
author_sort | da Silva, Fernanda Cardoso |
collection | PubMed |
description | Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies. |
format | Online Article Text |
id | pubmed-10610388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106103882023-10-28 Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer da Silva, Fernanda Cardoso Brandão, Douglas Cardoso Ferreira, Everton Allan Siqueira, Raoni Pais Ferreira, Helen Soares Valença Da Silva Filho, Ademar Alves Araújo, Thaise Gonçalves Pharmaceuticals (Basel) Review Breast cancer (BC) is the most diagnosed cancer worldwide, mainly affecting the epithelial cells from the mammary glands. When it expresses the estrogen receptor (ER), the tumor is called luminal BC, which is eligible for endocrine therapy with hormone signaling blockade. Hormone therapy is essential for the survival of patients, but therapeutic resistance has been shown to be worrying, significantly compromising the prognosis. In this context, the need to explore new compounds emerges, especially compounds of plant origin, since they are biologically active and particularly promising. Natural products are being continuously screened for treating cancer due to their chemical diversity, reduced toxicity, lower side effects, and low price. This review summarizes natural compounds for the treatment of luminal BC, emphasizing the activities of these compounds in ER-positive cells. Moreover, their potential as an alternative to endocrine resistance is explored, opening new opportunities for the design of optimized therapies. MDPI 2023-10-16 /pmc/articles/PMC10610388/ /pubmed/37895937 http://dx.doi.org/10.3390/ph16101466 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review da Silva, Fernanda Cardoso Brandão, Douglas Cardoso Ferreira, Everton Allan Siqueira, Raoni Pais Ferreira, Helen Soares Valença Da Silva Filho, Ademar Alves Araújo, Thaise Gonçalves Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer |
title | Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer |
title_full | Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer |
title_fullStr | Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer |
title_full_unstemmed | Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer |
title_short | Tailoring Potential Natural Compounds for the Treatment of Luminal Breast Cancer |
title_sort | tailoring potential natural compounds for the treatment of luminal breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610388/ https://www.ncbi.nlm.nih.gov/pubmed/37895937 http://dx.doi.org/10.3390/ph16101466 |
work_keys_str_mv | AT dasilvafernandacardoso tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer AT brandaodouglascardoso tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer AT ferreiraevertonallan tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer AT siqueiraraonipais tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer AT ferreirahelensoaresvalenca tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer AT dasilvafilhoademaralves tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer AT araujothaisegoncalves tailoringpotentialnaturalcompoundsforthetreatmentofluminalbreastcancer |